ArticleAnalytical chemistry2026
Self-Contained Lateral-Flow Microfluidic Bead-Based Assay for Rapid Quantification of Early-Stage Kidney Biomarkers.
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney diseases, whether acute or chronic, remain among the most challenging conditions to diagnose due to their complex and often asymptomatic progression. Emerging biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C (CysC) correlate with early pathogenesis and offer complementary insights into disease etiology. However, quantification of their levels, which is essential for patient staging, is available only in centralized laboratories. We present the lateral-flow microfluidic bead-based assay (LMBA), the first rapid, self-contained system for NGAL and CysC analysis. LMBA integrates a microfluidic chip with paper-based components to run automated high-resolution immunoassays in 20 min. Its modular architecture, decoupling reagent storage and flow control from assay binding and readout, offers significant design flexibility. Validated against ELISA, LMBA exhibits comparable sensitivity with an extended dynamic range, requiring only 1 μL of the original blood or urine sample prior to dilution. We applied the LMBA to neonatal mouse models of polycystic kidney disease and measured biomarker elevations consistent with cyst progression. This scalable platform supports preclinical research and holds strong potential for decentralized kidney disease diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.